Further query of the Breast Cancer METABRIC [29], for patients aged 55–60 with BRF2 alterations, ER positive status (n = 170) correlated with a decrease in overall survival, p = 7.87e-3, whereas ER negative status (n = 59) did not, p = 0.516 (Supplemental Table 1). This evidence concerns the gene BRF2 and breast carcinoma.